MITRA.BR Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:35):

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally...

Stats
Dzisiejszy wolumen	82 368.00
Średni wolumen	358 862
Kapitalizacja rynkowa	14.93M
EPS	€0 ( 2024-03-08 )
Następna data zysków	( €0 ) 2024-05-30
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.150
ATR14	€0.00100 (0.46%)

Mithra Pharmaceuticals SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mithra Pharmaceuticals SA Finanse

Annual	2023
Przychody:	€40.16M
Zysk brutto:	€5.99M (14.92 %)
EPS:	€-2.51

FY	2023
Przychody:	€40.16M
Zysk brutto:	€5.99M (14.92 %)
EPS:	€-2.51

FY	2022
Przychody:	€67.00M
Zysk brutto:	€35.43M (52.89 %)
EPS:	€-1.220

FY	2021
Przychody:	€22.67M
Zysk brutto:	€6.94M (30.63 %)
EPS:	€-1.114

Financial Reports:

No articles found.

Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.